ADC Therapeutics SA (ADCT)
1.075
-0.02
(-2.27%)
USD |
NYSE |
Jun 11, 16:00
1.075
0.00 (0.00%)
After-Hours: 20:00
ADC Therapeutics Research and Development Expense (Quarterly) : 19.88M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 19.88M |
| December 31, 2025 | 18.33M |
| September 30, 2025 | 26.80M |
| June 30, 2025 | 30.09M |
| March 31, 2025 | 28.93M |
| December 31, 2024 | 27.10M |
| September 30, 2024 | 32.50M |
| June 30, 2024 | 24.30M |
| March 31, 2024 | 25.74M |
| December 31, 2023 | 30.33M |
| September 30, 2023 | 27.08M |
| June 30, 2023 | 31.34M |
| March 31, 2023 | 38.38M |
| Date | Value |
|---|---|
| December 31, 2022 | 48.08M |
| September 30, 2022 | 41.45M |
| June 30, 2022 | 48.30M |
| March 31, 2022 | 48.70M |
| December 31, 2021 | 41.99M |
| September 30, 2021 | 36.67M |
| June 30, 2021 | 38.98M |
| March 31, 2021 | 38.98M |
| December 31, 2020 | 48.18M |
| September 30, 2020 | 32.01M |
| June 30, 2020 | 25.82M |
| March 31, 2020 | 35.23M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BeOne Medicines Ltd. | 521.31M |
| AC Immune SA | 14.99M |
| CRISPR Therapeutics AG | 66.37M |
| Idorsia Ltd. | 33.91M |
| MoonLake Immunotherapeutics | 53.67M |